Anticonvulsant Drug Development in Neurological Disorders

The landscape of anticonvulsant drug development has evolved from serendipitous discovery to mechanism-driven design, addressing not only classical epilepsy but also comorbid neurological conditions such as neuropathic pain and cognitive dysfunction following status epilepticus. Traditional compounds targeting voltage-gated sodium and calcium channels or enhancing γ-aminobutyric acid (GABA)ergic transmission have been complemented by novel scaffolds and modalities. Structure-based virtual screening, high-throughput electrophysiology and advanced animal seizure models have accelerated the identification of new chemical entities. In parallel, allosteric modulators of GABA and glutamate transporters seek to fine-tune synaptic inhibition without the adverse effects associated with older agents. Deep learning-driven repurposing pipelines and hybrid molecules integrating multiple pharmacophores have opened avenues for drug-resistant epilepsy. Safety, pharmacokinetics and blood–brain barrier permeability remain pivotal in early selection, while in vivo models such as maximal electroshock and pentylenetetrazole challenge tests continue to characterise efficacy. This integrated approach has produced candidates with broader spectra, improved tolerability and potential to ameliorate cognitive and mood sequelae of seizure disorders, underscoring global significance for both paediatric and adult populations.

Research from Nature Portfolio

Recent studies have harnessed transformer-based deep learning coupled with molecular docking and dynamics simulations to repurpose existing drugs against multiple epileptogenic targets. This pipeline identified unexpected high-affinity interactions for a cholesterol-lowering agent across key sodium and calcium channel subtypes, validated by binding assays and providing a cost-effective route to clinical translation. In parallel, cellular electrophysiology in hippocampal slices revealed how different antiseizure agents modulate spreading depolarization-induced epileptiform discharges. Classical sodium channel blockers markedly reduced paroxysmal depolarizations, whereas GABA uptake inhibitors exhibited moderate effects, informing combination strategies and target prioritisation at the neuronal level.

Anticonvulsant Drug Development in Neurological Disorders publication trend

The graph below shows the total number of articles in anticonvulsant drug development in neurological disorders across all publications each year (not limited to Nature Index journals).

Technical terms

In silico screening: Computational evaluation of compound libraries against molecular targets to predict binding affinity and selectivity.

Voltage-gated sodium channel (NaV): Transmembrane proteins responsible for rapid depolarisation in neurons, common targets of antiseizure drugs.

Positive allosteric modulator (PAM): A compound that binds to a distinct site on a receptor to enhance its response to the endogenous ligand without directly activating the receptor.

Maximal electroshock seizure (MES) model: An acute rodent assay inducing tonic seizures via electrical shock to assess anticonvulsant efficacy.

Subcutaneous pentylenetetrazole (scPTZ) model: A chemical induction method in rodents producing clonic seizures for evaluating anticonvulsant protection.

Drug repurposing: The strategy of identifying new therapeutic uses for approved or investigational drugs to reduce development time and cost.

Glutamate transporter EAAT2: A key astrocytic protein regulating extracellular glutamate levels and neuronal excitability, targeted by novel modulators.

References

1. In Silico Screening Identification of Fatty Acids and Fatty Acid Derivatives with Antiseizure Activity: In Vitro and In Vivo Validation. Pharmaceutics (2024).
2. Discovery of New 3-(Benzo[b]Thiophen-2-yl)Pyrrolidine-2,5-Dione Derivatives as Potent Antiseizure and Antinociceptive Agents—In Vitro and In Vivo Evaluation. Pharmaceuticals (2024).
3. In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy. Scientific Reports (2024).
4. Effects of anti-epileptic drugs on spreading depolarization-induced epileptiform activity in mouse hippocampal slices. Scientific Reports (2017).